Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

NCT04025632 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
27
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated based on the primary efficacy endpoint analysis after the first data lock.

Conditions

Interventions

Sponsor

Ra Pharmaceuticals